Concise Prescribing Info
Dosage/Direction for Use
Adult: PO 250 mg bid or tid. Max: 1,200 mg/day.
Should be taken with food. Take w/ or after meals.
Peptic ulcer. Severe renal impairment (CrCl <30 mL/min).
Special Precautions
Renal impairment (CrCl 30-60 mL/min). Monitoring Parameters Monitor hepatic and renal function. Measure lipid profile before treatment and serum lipids periodically.
Adverse Reactions
Peripheral vasodilatation, resulting in flushing, itching and sensation of heat; rash, erythema, heartburn, epigastric pain, nausea, diarrhoea, headache, myalgia, arthralgia, dry eye, malaise, myositis. Rarely, urticaria, angioedema, bronchospasm.
Drug Interactions
Risk of myopathy is increased when nicotinic acid is given concomitantly w/ a statin, as acipimox is structurally related to nicotinic acid, caution should be taken when used w/ such agents.
ATC Classification
C10AD06 - acipimox ; Belongs to the class of nicotinic acid and derivatives. Used in the treatment of hyperlipidemia.
Disclaimer: This information is independently developed by CIMS based on acipimox from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in